Evidence map›Paper›PMID 24732960›Full record

Trial reportBone marrow transplantation2014

A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

M Gotoh, S Yoshizawa, S Katagiri, T Suguro, M Asano, T Kitahara, D Akahane, S Okabe, T Tauchi, Y Ito and 1 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

M GotohDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
S YoshizawaDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
S KatagiriDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
T SuguroDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
M AsanoDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
T KitaharaDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
D AkahaneDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
S OkabeDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
T TauchiDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
Y ItoDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
K OhyashikiDivision of Hematology, The First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-remitting patients with hematologic myeloid malignancies have poor prognosis. To overcome this problem, we investigated the use of reduced-intensity preconditioning umbilical cord blood transplantation (RICBT) combined with recombinant G-CSF (rG-CSF) with high-dose Ara-C, fludarabine, melphalan, and 4 Gy of TBI in a phase I/II study in patients with non-remitting myeloid hematologic malignancies. Thirteen patients were enrolled, including 12 with non-remitting AML and one patient with blastic crisis CML (CML-BC). The patients' median age was 45 years, with a median comorbidity index of 4. All patients received 4/6 serological HLA-antigen matched unrelated umbilical cord blood. All patients were engrafted within 30 days after RICBT (median, 20 days; range, 14-29) and achieved complete remission without prior hematopoiesis. Common grade III non-hematologic toxicities included eight cases of transient mucositis (62%) and six cases of febrile neutropenia (46%). Transplant-related mortality was 7.7%. The 1-year overall survival was 28.6% in cases without post-RICBT treatment and 83.3% in cases with post-RICBT treatment. These data suggest that in active AML and CML-BC, the combination of rG-CSF with high-dose Ara-C and fludarabine/melphalan/4 Gy TBI with a reduced-intensity preconditioning regimen is well tolerated, secures engraftment and has significant anti-leukemia activity. In addition, performing post-RICBT treatment may provide high-quality long-term survival and remission.

Indexed as

AdultAgedAntimetabolites, AntineoplasticCord Blood Stem Cell TransplantationCytarabineFemaleGranulocyte Colony-Stimulating FactorHematologic NeoplasmsHumansMaleMiddle AgedPrognosisYoung AdultAntimetabolites, AntineoplasticCytarabineGranulocyte Colony-Stimulating Factor

Identifiers

PMID24732960
OpenAlexW1977764464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.